A phase III study assessing Fenebrutinib for relapsing multiple sclerosis
Latest Information Update: 14 Sep 2020
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FENhance 1
- Sponsors Genentech
- 14 Sep 2020 New trial record